Prospect of Direct Benefit in Pediatric Trials: Practical Challenges and Potential Solutions

Clinical research in pediatric patients is necessary to develop safe and effective medicines for children. US Food and Drug Administration (FDA) human subject protection regulations (21 Code of Federal Regulations 50, subpart D) require that, with limited exceptions, research in children that exceed...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 2021-05, Vol.147 (5), p.1
Main Authors: Bhatnagar, Melanie, Sheehan, Sarah, Sharma, Isha, Baer, Gerri, Green, Dionna, McCune, Susan, Joffe, Steven, Snyder, Donna
Format: Article
Language:English
Subjects:
Children
Clinical trials
Company business management
Conferences, meetings and seminars
Dosage
Ethical aspects
Federal regulation
Management
Patients
Pediatric research
Pediatrics
Product development
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical research in pediatric patients is necessary to develop safe and effective medicines for children. US Food and Drug Administration (FDA) human subject protection regulations (21 Code of Federal Regulations 50, subpart D) require that, with limited exceptions, research in children that exceeds a defined level of risk must offer a prospect of direct benefit to the individual child that is sufficient to justify those risks. Growing attention to the merits of initiating pediatric clinical trials earlier in the drug and biological product development process has led the FDA to look more closely at the meaning of the regulatory term prospect of direct benefit. In collaboration with the FDA, the Duke-Margolis Center for Health Policy convened a workshop with leading experts in the fields of biomedical ethics, pediatric clinical research, and pediatric product development, as well as patient representatives, to discuss the FDA's approach to characterizing prospect of direct benefit in the context of scientific advances in product development. Workshop topics included the extrapolation of adult efficacy data to children, use of nonclinical models of disease, use of modeling and simulation to support pediatric dosing, and reliance on biomarkers and surrogate end points in clinical research. Discussion from the workshop is provided herein to communicate the challenges that investigators, industry sponsors, regulators, and institutional review boards face when evaluating pediatric research and to outline several approaches to maximize prospect of direct benefit, minimize unnecessary risks and burden, and facilitate timely access to safe and effective medicines for children.
ISSN:0031-4005
1098-4275
DOI:10.1542/peds.2020-049602